Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Tongue Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × advexin × Clear all
NCT02842125 2020-06-02

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

MultiVir, Inc.

Phase 1/2 Terminated
4 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡